EA200602080A1 - Пиперазиновые производные алкилоксиндолов - Google Patents

Пиперазиновые производные алкилоксиндолов

Info

Publication number
EA200602080A1
EA200602080A1 EA200602080A EA200602080A EA200602080A1 EA 200602080 A1 EA200602080 A1 EA 200602080A1 EA 200602080 A EA200602080 A EA 200602080A EA 200602080 A EA200602080 A EA 200602080A EA 200602080 A1 EA200602080 A1 EA 200602080A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkylsiloids
derivatives
piperizine
piperizine derivatives
indol
Prior art date
Application number
EA200602080A
Other languages
English (en)
Other versions
EA011280B1 (ru
Inventor
Балаж Вольк
Йожеф Баркоци
Дьюла Шимиг
Тибор Мезеи
Рита Каппилерне Дежёфи
Иштван Гачальи
Каталин Паллаги
Габор Гиглер
Дьёрдь Леваи
Кристина Мориц
Чилла Левелеки
Нора Сираи
Габор Сенаши
Андраш Эдьед
Ласло Габор Харсинг
Original Assignee
Эгиш Дьёдьсердьяр Нирт.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0400954A external-priority patent/HU0400954D0/hu
Priority claimed from HU0500461A external-priority patent/HUP0500461A3/hu
Application filed by Эгиш Дьёдьсердьяр Нирт. filed Critical Эгиш Дьёдьсердьяр Нирт.
Publication of EA200602080A1 publication Critical patent/EA200602080A1/ru
Publication of EA011280B1 publication Critical patent/EA011280B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Настоящее изобретение относится к новым производным индол-2-она общей формулы (I). Новые соединения применимы для лечения или профилактики нарушений центральной нервной системы или сердечно-сосудистой системы.
EA200602080A 2004-05-11 2005-05-10 Пиперазиновые производные алкилоксиндолов EA011280B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0400954A HU0400954D0 (en) 2004-05-11 2004-05-11 Piperazine derivatives of alkyl oxindoles
HU0500461A HUP0500461A3 (en) 2005-05-05 2005-05-05 Pyperazine derivatives of alkyl-oxindoles
PCT/HU2005/000048 WO2005108363A1 (en) 2004-05-11 2005-05-10 Piperazine derivatives of alkyl oxindoles

Publications (2)

Publication Number Publication Date
EA200602080A1 true EA200602080A1 (ru) 2007-04-27
EA011280B1 EA011280B1 (ru) 2009-02-27

Family

ID=89985994

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200602080A EA011280B1 (ru) 2004-05-11 2005-05-10 Пиперазиновые производные алкилоксиндолов

Country Status (24)

Country Link
US (1) US20070219209A1 (ru)
EP (1) EP1751106B1 (ru)
JP (1) JP2007537226A (ru)
KR (1) KR20070011551A (ru)
AT (1) ATE412634T1 (ru)
AU (1) AU2005240842B2 (ru)
BG (1) BG109768A (ru)
CA (1) CA2564009A1 (ru)
CZ (1) CZ2006778A3 (ru)
DE (1) DE602005010694D1 (ru)
DK (1) DK1751106T3 (ru)
EA (1) EA011280B1 (ru)
ES (1) ES2317241T3 (ru)
HR (2) HRP20060401A2 (ru)
IL (1) IL178759A0 (ru)
MX (1) MXPA06013064A (ru)
NO (1) NO20065697L (ru)
NZ (1) NZ551542A (ru)
PL (1) PL1751106T3 (ru)
PT (1) PT1751106E (ru)
RS (1) RS20060620A (ru)
SI (1) SI1751106T1 (ru)
SK (1) SK51112006A3 (ru)
WO (1) WO2005108363A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ551547A (en) * 2004-05-11 2010-06-25 Egis Gyogyszergyar Nyrt 3-(((4-phenyl)-piperazine-1-yl)-alkyl)-3-alkyl-1,3-dihydro-2H-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders
CN106243088B (zh) 2015-06-03 2019-01-04 广东东阳光药业有限公司 取代的哌嗪化合物及其使用方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452808A (en) * 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
FR2635104B1 (fr) * 1988-08-03 1992-04-30 Synthelabo Derives d'indolone, leur preparation et leur application en therapeutique
GB8830312D0 (en) * 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
WO1998008816A1 (fr) * 1996-08-26 1998-03-05 Meiji Seika Kaisha, Ltd. Derives d'indoxyle et psychotropes

Also Published As

Publication number Publication date
DE602005010694D1 (de) 2008-12-11
KR20070011551A (ko) 2007-01-24
WO2005108363A1 (en) 2005-11-17
EA011280B1 (ru) 2009-02-27
BG109768A (bg) 2008-03-31
MXPA06013064A (es) 2007-04-27
AU2005240842B2 (en) 2011-10-06
US20070219209A1 (en) 2007-09-20
CA2564009A1 (en) 2005-11-17
ATE412634T1 (de) 2008-11-15
EP1751106A1 (en) 2007-02-14
NZ551542A (en) 2010-06-25
PL1751106T3 (pl) 2009-07-31
ES2317241T3 (es) 2009-04-16
IL178759A0 (en) 2007-02-11
DK1751106T3 (da) 2009-03-09
RS20060620A (en) 2008-09-29
CZ2006778A3 (cs) 2007-03-07
HRP20090054T3 (en) 2009-03-31
AU2005240842A1 (en) 2005-11-17
SK51112006A3 (sk) 2007-05-03
EP1751106B1 (en) 2008-10-29
SI1751106T1 (sl) 2009-06-30
PT1751106E (pt) 2009-02-10
JP2007537226A (ja) 2007-12-20
HRP20060401A2 (en) 2007-03-31
NO20065697L (no) 2007-02-02

Similar Documents

Publication Publication Date Title
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
SE0203713D0 (sv) Novel compounds
SE0201635D0 (sv) Novel compounds
GB0510141D0 (en) Novel compounds B3
BRPI0410711A (pt) novos compostos
EA200700909A1 (ru) Азаиндолкарбоксамиды
EA201100749A1 (ru) Производные пиридина и пиримидина в качестве ингибиторов фосфодиэстеразы 10
MXPA06014721A (es) Derivados de alquinilo como moduladores de los receptores de glutamato metabotropico.
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
TW200728258A (en) Novel compounds
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
TW200740766A (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands
MX2008002158A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6.
EA201001872A1 (ru) Новые способы получения производных циклопропиламида
EA200602081A1 (ru) Пиридиновые производные алкилоксиндолов в качестве агентов, активных в отношении рецептора 5-нт7
EA200602080A1 (ru) Пиперазиновые производные алкилоксиндолов
EA200602084A1 (ru) Пиперазиновые производные алкилоксиндолов
EA200602083A1 (ru) Новые пиперазиновые производные диалкилоксиндолов
IL179030A0 (en) Indol-2-one derivatives for the treatment of central nervous disorders, gastrointestinal disorders and cardiovascular disorders
ATE479691T1 (de) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren
UA86809C2 (en) Piperazine derivatives of alkyl oxindoles

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU